Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Invivyd, Inc.
  6. Company
    IVVD   US00534A1025

INVIVYD, INC.

(IVVD)
  Report
Delayed Nasdaq  -  01:00 2022-11-25 pm EST
2.140 USD   -5.31%
11/17Invivyd Says it Teamed Up With Population Health Partners to Accelerate Clinical Development Projects
MT
11/17Invivyd, Inc. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/17Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Logo Invivyd, Inc.
Invivyd, Inc., formerly Adagio Therapeutics, Inc., is a biopharmaceutical company. The company is engaged in developing antibodies to transcend the limits of naturally occurring immunity and provide protection from viral diseases, beginning with COVID-19. Its technology works at the intersection of virology, predictive modeling, and antibody engineering. Its platform approach yields a pipeline of engineered antibodies designed to provide neutralization across past and current SARS-CoV-2 variants of concern, including wildtype, Beta, Delta, and Omicron BA.1, BA.2, BA.5, and BA.2.75. The Company generates a pipeline of products for use in both the prevention and treatment of disease. Its advanced pipeline candidate includes adintrevimab, an investigational monoclonal antibody that is used against multiple variants of concern for the prevention and treatment of COVID-19. The Company also has multiple discovery stage candidates for the prevention of seasonal influenza.

Number of employees : 103 people.
Managers
Name Title Age Since
David Hering Chief Executive Officer & Director 46 2022
Frederick W. Driscoll Chief Financial & Accounting Officer 70 2022
Laura Walker Chief Scientific Officer 37 2020
Rebecca Dabora Chief Technology & Manufacturing Officer 63 2020
Jill Andersen Secretary & Chief Legal Officer - -
Elham Hershberger, Dr. Chief Development Officer 54 2020
Julie Green Senior Vice President-Human Resources - -
Members of the board
Name Title Age Since
Marc W. Elia Chairman 45 2022
Tomas Jan Heyman Independent Director 66 2021
Terrance G. McGuire Director 64 -
David Hering Chief Executive Officer & Director 46 2022
Michael S. Wyzga Director 66 2021
Tamsin Berry Director 40 2022
Clive Meanwell Director 64 2022
Christine Regan Lindenboom Director - 2022
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 108,982,401 78,977,760 72.5% 0 0.0% 72.5%
Shareholders
NameEquities%
Adimab LLC 26,687,906 24.3%
Mithril Capital Management LLC 11,241,580 10.2%
M28 Capital Management LP 9,248,250 8.41%
Polaris Growth Management LLC 8,531,700 7.76%
Fidelity Management & Research Co. LLC 8,435,631 7.67%
Alphabet Inc. 5,680,785 5.17%
OrbiMed Advisors Private Equity 5,056,000 4.60%
RA Capital Management LP 4,995,807 4.54%
Slate Path Capital LP 3,735,000 3.40%
683 Capital Management LLC 3,603,637 3.28%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Invivyd, Inc.
Sector Bio Therapeutic Drugs